Monday, September 18, 2017 11:39:47 AM
http://ir.vblrx.com/static-files/8e6ca5af-3400-4be6-b333-3856915a8454
Dear Sir/Madam,
in your corporate presentation (linked above) dated June 2017 you report median Overall Survival for the rGBM ph2 trial of 15 months (slides page 10) and then 59.1 weeks in slide 21 (ca 13.6m). Can you please explain the difference?
Moreover , and more importantly, you report a median OS of 810 days for the therapeutic dose platinum resistant ovarian cancer ph2 trial, whereas on slide 14, where you report number of patients living longer than 15 months, it appears that the median patient has lived 15.7 months. Where do you get this 810 days Median OS from?
Since this is very material information for investors, I would be most grateful if you could clarify the above.
Thanks and regards.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM